Conference call and webcast on Wednesday, September 18 at 2:30 pm CET/8:30 am EDT
- TRYbeCA1, Phase 3 trial for eryaspase in second line pancreatic cancer, progressing on plan
- Immune modulation collaboration entered into with SQZ Biotechnologies
- Board strengthened with appointment of Dr. Jean Paul Kress as Chairman
- Cash position of €94.5 million ($107.5 million) at the end of June